O Futuro da Pfizer (PFE): Uma Narrativa de Transição e Resiliência No final de 2025, a Pfizer Inc. (PFE) encontra-se em um momento pivotal de sua história.Read more
I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines.Read more
Pfizer could be closer to a rebound than the market expects if its cost cuts, faster drug approvals, and push into cancer treatments and fast-growing countries start paying off sooner. But looming patent cliffs and tougher rules on drug pricing could still squeeze sales and profits, making the next few years pivotal.Read more
Pfizer is trying to replace fading blockbuster medicines by leaning harder into cancer and rare-disease treatments, new vaccines, and deals that add fresh products to its pipeline. The big question is whether these new launches and expansion into faster-growing countries can outpace pricing pressure, tougher competition, and looming patent losses.Read more
Key Takeaways Aggressive drug pricing negotiations, regulatory reforms, and patent expirations are constraining Pfizer's revenue growth and squeezing profit margins across key markets. Heavy reliance on new R&D assets to replace aging drugs poses significant risk, as declining exclusivity and increased competition may outpace innovative product launches.Read more
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
